Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma: Difference between revisions

From STARDIT
Jump to navigation Jump to search
VisualWikitext
wikispore>Pkdilena
No edit summary
wikispore>Jacknunn
No edit summary
Line 2: Line 2:
|type_parameter=research
|type_parameter=research
|description_parameter=Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
|description_parameter=Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
|aim_parameter={{aim parameter|maximise survival of these young Australians}}
|aim_parameter={{aim parameter|maximise survival of young Australians with Hodgkin Lymphoma}}
|state_parameter=ongoing
|state_parameter=ongoing
|start_date_parameter=2021-01-01
|start_date_parameter=2021-01-01
Line 12: Line 12:
|aut_nam=Portia Dilena
|aut_nam=Portia Dilena
|aut_url=https://scholars.latrobe.edu.au/pdilena
|aut_url=https://scholars.latrobe.edu.au/pdilena
|aut_con=non contact
}}{{author parameter
|aut_nam=Jack Nunn
|aut_url=https://orcid.org/0000-0003-0316-3254
|aut_tas=Checked STARDIT report data
|aut_con=non contact
|aut_con=non contact
}}
}}

Revision as of 00:46, 15 November 2023

Description: Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 per cent of patients are cured with front line treatment, 30 per cent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL to maximise survival of these young Australians.
Dates

State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-11-15

Report authors
Portia Dilena (link)
Jack Nunn (link)
Checked STARDIT report data
Aims
maximise survival of young Australians with Hodgkin Lymphoma
Category
research

Inputs

individual

Eliza Hawkes


Task: Lead Chief Investigator
Compensation: paid
funding

(link)


1,225,487.40 (AUD)

Outputs and impacts

Retrieved from "https://stardit.wikimedia.org.au/w/index.php?title=Employing_rational_novel_agent_combination_therapy_to_improve_transplant_cure_rates_for_relapsed/refractory_Hodgkin_Lymphoma&oldid=326"